Tg Therapeutics (TGTX) Debt to Equity: 2019-2025
Historic Debt to Equity for Tg Therapeutics (TGTX) over the last 7 years, with Sep 2025 value amounting to $0.40.
- Tg Therapeutics' Debt to Equity fell 68.20% to $0.40 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.40, marking a year-over-year decrease of 68.20%. This contributed to the annual value of $1.10 for FY2024, which is 76.22% up from last year.
- According to the latest figures from Q3 2025, Tg Therapeutics' Debt to Equity is $0.40, which was down 54.42% from $0.89 recorded in Q2 2025.
- In the past 5 years, Tg Therapeutics' Debt to Equity ranged from a high of $3.52 in Q1 2023 and a low of $0.05 during Q3 2021.
- In the last 3 years, Tg Therapeutics' Debt to Equity had a median value of $0.89 in 2025 and averaged $1.19.
- In the last 5 years, Tg Therapeutics' Debt to Equity skyrocketed by 1,278.44% in 2022 and then tumbled by 82.01% in 2024.
- Quarterly analysis of 5 years shows Tg Therapeutics' Debt to Equity stood at $0.29 in 2021, then skyrocketed by 324.93% to $1.21 in 2022, then tumbled by 48.63% to $0.62 in 2023, then spiked by 76.22% to $1.10 in 2024, then slumped by 68.20% to $0.40 in 2025.
- Its Debt to Equity stands at $0.40 for Q3 2025, versus $0.89 for Q2 2025 and $1.03 for Q1 2025.